Berlin, Germany
Sanity Group, established in 2018, operates at the intersection of Biotechnology, Health Care, and Health and Wellness. Headquartered in Germany, the company is committed to incorporating cannabinoids into innovative pharmaceuticals and consumer health products, as reflected in their slogan: "Unlocking the potential of cannabinoids to develop innovative pharmaceuticals and consumer health products."
The company's diverse operations encompass both medicinal cannabis and consumer health, setting it apart in an increasingly competitive market. Their mission to enhance health and wellness provides them with a promising trajectory as they expand their presence across Europe and seek international cultivation partners.
The latest financial development occurred on June 25, 2024, with a €2.50M investment from the secondary market, primarily backed by OrganiGram. This investment reinforces the company's growth potential and their appealing market positioning in Europe.
TTS Pharma Ltd
